The management of transitional cell carcinoma (TCC) in a European regional renal transplant population

BJU International

Volumn 110, Issue , 2012, Pages

  Rogers, Alistair ^a   Koo Ng, Jenny ^b   Glendinning, James ^c   Rix, David ^a  

^a FREEMAN HOSPITAL   (United Kingdom)

^b JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^c SUNDERLAND ROYAL HOSPITAL   (United Kingdom)

Author keywords

immunosuppression; renal transplant; transitional cell carcinoma (TCC)

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; PREDNISOLONE; RAPAMYCIN; TACROLIMUS;

ADULT; AGED; BLADDER TUMOR; CANCER GRADING; CANCER INVASION; CANCER RISK; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL ARTICLE; CYSTOSCOPY; DISEASE ASSOCIATION; EUROPE; FOLLOW UP; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; METASTASIS; NEPHROURETERECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENT CANCER; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SUPERFICIAL CANCER; SURVIVAL RATE; SURVIVAL TIME; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION;

ADULT; AGED; CARCINOMA, TRANSITIONAL CELL; CYSTOSCOPY; EUROPE; HUMANS; KIDNEY TRANSPLANTATION; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; URETERAL NEOPLASMS; URINARY BLADDER NEOPLASMS;

EID: 84863554248     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10777.x     Document Type: Review

References (52)

1. Hunsicker LG,. A survival advantage for renal transplantation. N Engl J Med 1999; 341: 1762-3
2. Gaya SB, Rees AJ, Lechler RI, Williams G, Mason PD,. Malignant disease in patients with long-term renal transplants. Transplantation 1995; 59: 1705-9
3. Villeneuve PJ, Schaubel DE, Fenton SS, Shepherd FA, Jiang Y, Mao Y,. Cancer incidence among Canadian kidney transplant recipients. Am J Transplant 2007; 7: 941-8
4. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C,. Cancer after kidney transplantation in the United States. Am J Transplant 2004; 4: 905-13
5. Ochiai T, Asano T, Isono K,. Development of malignancies in Japanese renal transplant recipients. Transplant Proc 1987; 19: 2967-70
6. Qunibi W, Akhtar M, Sheth K, et al,. Kaposi's sarcoma: the most common tumor after renal transplantation in Saudi Arabia. Am J Med 1988; 84: 225-32
7. Wu MJ, Lian JD, Yang CR, et al,. High cumulative incidence of urinary tract transitional cell carcinoma after kidney transplantation in Taiwan. Am J Kidney Dis 2004; 43: 1091-7
8. Feng WW, Wang TN, Chen HC, Ho JC, Ko YC,. Malignancies after renal transplantation in southern Taiwan: experience in one centre. BJU Int 2007; 99: 825-9
9. Penn I,. Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transpl 1998; 12: 147-58
10. Besarani D, Cranston D,. Urological malignancy after renal transplantation. BJU Int 2007; 100: 502-5
11. Muruve NA, Shoskes DA,. Genitourinary malignancies in solid organ transplant recipients. Transplantation 2005; 80: 709-16
12. Buzzeo BD, Heisey DM, Messing EM,. Bladder cancer in renal transplant recipients. Urology 1997; 50: 525-8
13. Kamal MM, Soliman SM, Shokeir AA, Abol-Enein H, Ghoneim MA,. Bladder carcinoma among live-donor renal transplant recipients: a single-centre experience and a review of the literature. BJU Int 2008; 101: 30-5
14. Gifford RR, Wofford JE, Edwards WG Jr,. Carcinoma of the bladder in renal transplant patients. A case report and collective review of cases. Clin Transplant 1998; 12: 65-9
15. Wang HB, Hsieh HH, Chen YT, Chiang CY, Cheng YT,. The outcome of post-transplant transitional cell carcinoma in 10 renal transplant recipients. Clin Transplant 2002; 16: 410-3
16. Kao YL, Ou YC, Yang CR, Ho HC, Su CK, Shu KH,. Transitional cell carcinoma in renal transplant recipients. World J Surg 2003; 27: 912-6
17. Master VA, Meng MV, Grossfeld GD, Koppie TM, Hirose R, Carroll PR,. Treatment and outcome of invasive bladder cancer in patients after renal transplantation. J Urol 2004; 171: 1085-8
18. Elkentaoui H, Robert G, Pasticier G, et al,. Therapeutic management of de novo urological malignancy in renal transplant recipients: the experience of the French Department of Urology and Kidney Transplantation from Bordeaux. Urology 2010; 75: 126-32
19. Li XB, Xing NZ, Wang Y, Hu XP, Yin H, Zhang XD,. Transitional cell carcinoma in renal transplant recipients: a single center experience. Int J Urol 2008; 15: 53-7
20. Lang H, de Petriconi R, Wenderoth U, Volkmer BG, Hautmann RE, Gschwend JE,. Orthotopic ileal neobladder reconstruction in patients with bladder cancer following renal transplantation. J Urol 2005; 173: 881-4
21. Palou J, Angerri O, Segarra J, et al,. Intravesical bacillus Calmette-Guerin for the treatment of superficial bladder cancer in renal transplant patients. Transplantation 2003; 76: 1514-6
22. Lemmers MJ, Barry JM,. De novo carcinoma of the lower urinary tract in renal allograft recipients. J Urol 1990; 144: 1233-5
23. Schmidt R, Stippel D, Krings F, Pollok M,. Malignancies of the genito-urinary system following renal transplantation. Br J Urol 1995; 75: 572
24. Liao CH, Chueh SC, Lai MK, Chen J,. Transitional cell carcinoma in renal transplant recipients. Transplant Proc 2004; 36: 2152-3
25. Einollahi B, Simforoosh N, Lessan-Pezeshki M, et al,. Genitourinary tumor following kidney transplantation: a multicenter study. Transplant Proc 2009; 41: 2848-9
26. McInerney PD, Koffman CG, Mundy AR,. Human papillomavirus-related bladder cancer following renal transplantation. Br J Urol 1993; 72: 663-4
27. Querci della Rovere G, Oliver RT, McCance DJ, Castro JE,. Development of bladder tumour containing HPV type 11 DNA after renal transplantation. Br J Urol 1988; 62: 36-8
28. Perabo FG, Schultze-Seemann W., Continent orthotopic ileal neobladder after kidney transplant in a female patient with multifocal transitional cell carcinoma. J Urol 1998; 159: 1635-6
29. Colombo T, Zigeuner R, Zitta S, Petritsch PH, Hubmer G,. Othotopic neobladder in a woman after kidney transplantation. J Urol 1997; 158: 2236-7
30. Giessing M, Türk I, Schoenberger B, Loening SA,. Orthotopic neobladder after kidney transplantation in a male patient with recurring urothelial carcinoma and renal cancer. J Urol 2001; 166: 1383
31. Biggs AW., Carcinoma of the bladder in a renal transplant patient. J Urol 1973; 109: 417
32. Embrey J, Silva F, Helderman H, Peters P, Sagalowsky A,. Long term survival and late development of bladder cancer in a renal transplant patient with progressive multifocal leukoencephalopathy. J Urol 1988; 139: 580
33. Thomalla J, Leapman S, Filo R,. Fatal transitional cell carcinoma of bladder in renal transplant recipient. Urol 1991; 38: 567
34. Swindle P, Falk M, Rigby R, Petrie J, Hawley C, Nicol D,. Transitional cell carcinoma in renal transplant recipients: the influence of compound analgesics. Br J Urol 1998; 81: 229-33
35. Thon WF, Kliem V, Truss MC, et al,. Denovo urothelial carcinoma of the upper and lower urinary tract in kidney-transplant patients with end-stage analgesic nephropathy. World J Urol 1995; 13: 254-61
36. Birkeland SA,. Malignant tumors in renal transplant patients. The Scandia transplant material. Cancer 1983; 51: 1571-5
37. Barr BB, Benton EC, McLaren K, et al,. Human papilloma virus infection and skin cancer in renal allograft recipients. Lancet 1989; 1: 124-9
38. London NJ, Farmery SM, Will EJ, Davison AM, Lodge JP,. Risk of neoplasia in renal transplant patients. Lancet 1995; 346: 403-6
39. Nortier JL, Martinez MC, Schmeiser HH, et al,. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 2000; 342: 1686-92
40. Li HZ, Xia M, Han Y, Xu XG, Zhang YS,. De novo urothelial carcinoma in kidney transplantation patients with end-stage aristolochic acid nephropathy in China. Urol Int 2009; 83: 200-5
41. Peng Z,. Should prophylactic native bilateral nephroureterectomy be an optimum method for renal transplant recipients with urinary tract malignancy? J Urol 2009; 181: 746 (abstract)
42. Tuttle TM, Williams GM, Marshall FF,. Evidence for cyclophosphamide- induced transitional cell carcinoma in a renal transplant patient. J Urol 1988; 140: 1009-11
43. Ansher AF, Melton JW 3rd, Sliwinski AJ,. Bladder malignancy in a patient receiving low dose cyclophosphamide for treatment of rheumatoid arthritis. Arthritis Rheum 1983; 26: 804-5
44. Samra Y, Hertz M, Lindner A,. Urinary bladder tumors following cyclophosphamide therapy: a report of two cases with a review of the literature. Med Pediatr Oncol 1985; 13: 86-91
45. Johnson WW, Meadows DC,. Urinary-bladder fibrosis and telangiectasia associated with long-term cyclophosphamide therapy. N Engl J Med 1971; 284: 290-4
46. Alvarado Y, Mita MM, Vemulapalli S, Mahalingam D, Mita AC,. Clinical activity of mammalian target of rapamycin inhibitors in solid tumors. Target Oncol 2011; 6: 69-94
47. Sanchez-Fructuoso A, Conesa J, Perez Flores I, et al,. Conversion to sirolimus in renal transplant patients with tumors. Transplant Proc 2006; 38: 2451-2
48. Kolhe N, Mamode N, Van der Walt J, Pattison J,. Regression of post-transplant Kaposi's sarcoma using sirolimus. Int J Clin Pract 2006; 60: 1509-12
49. Branco F, Cavadas V, Osorio L, et al,. The incidence of cancer and potential role of sirolimus immunosuppression conversion on mortality among a single-center renal transplantation cohort of 1,816 patients. Transplant Proc 2011; 43: 137-41
50. Reichelt O, Wunderlich H, Neiser G, Schubert J,. How reliable is conventional urinary cytology in post-transplant patients? Urol Int 2003; 71: 176-7
51. Kalble T, Alcaraz A, Budde K, et al,. European Urology Guidelines on Renal Transplantation. Available at:. Accessed October 2011
52. Neuzillet Y, Davin JL, Lechevallier E,. [Intravesical BCG instillations for the treatment of superficial bladder tumours in renal transplant recipients]. Prog Urol 2006; 16: 32-5